MedTrace Logo

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

NCT01990248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 339

Last updated 2018-06-19

No results posted yet for this study

Summary

This multi-center, prospective, observational safety study will evaluate the safety and effectiveness of Zelboraf (vemurafenib) in a real world setting. Data from Zelboraf-treated patients with BRAF-V600 mutation-positive unresectable or metastatic melanoma will be collected for 2 years.

Conditions

  • Malignant Melanoma

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-23
Primary Completion
2016-07-26
Completion
2016-07-26

Countries

  • Austria
  • Belgium
  • Czechia
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Poland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990248 on ClinicalTrials.gov